Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company that focuses on developing T cell receptor-based therapeutics. The company is known for its innovative approach in treating cancer, infectious diseases, and autoimmune conditions. In the competitive landscape, Immunocore stands alongside peers like Vor Biopharma Inc. (VOR), Cullinan Therapeutics, Inc. (CGEM), Sana Biotechnology, Inc. (SANA), and Design Therapeutics, Inc. (DSGN).
In evaluating Immunocore's financial performance, the Return on Invested Capital (ROIC) is a critical metric. IMCR's ROIC is -4.49%, which is below its Weighted Average Cost of Capital (WACC) of 6.55%. This results in a ROIC to WACC ratio of -0.68, indicating that the company is not generating returns above its cost of capital. However, compared to its peers, IMCR's capital efficiency is relatively better.
Vor Biopharma Inc. (VOR) has a significantly lower ROIC of -232.79% against a WACC of 9.33%, leading to a ROIC to WACC ratio of -24.95. This suggests that VOR is struggling more with capital efficiency compared to IMCR. Similarly, Cullinan Therapeutics, Inc. (CGEM) and Sana Biotechnology, Inc. (SANA) also show negative ROIC to WACC ratios of -11.508 and -6.208, respectively, indicating less efficient capital utilization than IMCR.
Design Therapeutics, Inc. (DSGN) stands out with the highest ROIC to WACC ratio among the peers at -3.055. IMCR's position is relatively strong, with a better ROIC to WACC ratio than most of its peers, highlighting its potential for improvement in capital utilization.
